Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 4 , Pages 621-640 , December 2007

Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus

  • Shlomit Koren, MD (Research Fellow, Internal Medicine and Endocrinology and Metabolism, Department of Medicine and Banting and Best Diabetes Center, University of Toronto)
  • I. George Fantus, MD, FRCP(C) (Professor, Department of Medicine and Physiology and Director, Division of Endocrinology and Metabolism, University of Toronto)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: 416 586 8665; Fax: 416 361 2657.

References 

  1. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nature Reviews. Molecular Cell Biology. 2006 Nov;7(11):833–846
  2. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nature Reviews. Molecular Cell Biology. 2006 Feb;7(2):85–96
  3. Hornberg JJ, Bruggeman FJ, Binder B, et al. Principles behind the multifarious control of signal transduction. ERK phosphorylation and kinase/phosphatase control. The FEBS Journal. 2005 Jan;272(1):244–258
  4. Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nature Reviews. Cancer. 2006 Apr;6(4):307–320
  5. Alonso A, Sasin J, Bottini N, et al. Protein tyrosine phosphatases in the human genome. Cell. 2004 Jun 11;117(6):699–711
  6. Elchebly M, Cheng A, Tremblay ML. Modulation of insulin signaling by protein tyrosine phosphatases. Journal of Molecular Medicine. 2000;78(9):473–482
  7. Goldstein BJ. Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance. Current Drug Targets. Immune, Endocrine and Metabolic Disorders. 2001 Nov;1(3):265–275
  8. Buist A, Zhang YL, Keng YF, et al. Restoration of potent protein-tyrosine phosphatase activity into the membrane-distal domain of receptor protein-tyrosine phosphatase alpha. Biochemistry. 1999 Jan 19;38(3):914–922
  9. Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Molecular Cell. 2002 Feb;9(2):387–399
  10. Groen A, Lemeer S, van der Wijk T, et al. Differential oxidation of protein-tyrosine phosphatases. The Journal of Biological Chemistry. 2005 Mar 18;280(11):10298–10304
  11. Wishart MJ, Dixon JE. Gathering STYX: phosphatase-like form predicts functions for unique protein-interaction domains. Trends in Biochemical Sciences. 1998 Aug;23(8):301–306
  12. Robinson FL, Dixon JE. The phosphoinositide-3-phosphatase MTMR2 associates with MTMR13, a membrane-associated pseudophosphatase also mutated in type 4B Charcot–Marie–Tooth disease. The Journal of Biological Chemistry. 2005 Sep 9;280(36):31699–31707
  13. Kim SA, Vacratsis PO, Firestein R, et al. Regulation of myotubularin-related (MTMR)2 phosphatidylinositol phosphatase by MTMR5, a catalytically inactive phosphatase. Proceedings of the National Academy of Sciences of the United States of America. 2003 Apr 15;100(8):4492–4497
  14. White MF, Kahn CR. The insulin signaling system. The Journal of Biological Chemistry. 1994 Jan 7;269(1):1–4
  15. Johnson TO, Ermolieff J, Jirousek MR. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nature Reviews. Drug discovery. 2002 Sep;1(9):696–709
  16. Fantus IG, Tsiani E. Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects. Molecular and Cellular Biochemistry. 1998 May;182(1–2):109–119
  17. Goldstein BJ, Mahadev K, Wu X, et al. Role of insulin-induced reactive oxygen species in the insulin signaling pathway. Antioxid Redox Signal. 2005 Jul–Aug;7(7–8):1021–1031
  18. Mahadev K, Motoshima H, Wu X, et al. The NAD(P)H oxidase homolog Nox4 modulates insulin-stimulated generation of H2O2 and plays an integral role in insulin signal transduction. Molecular and Cellular Biology. 2004 Mar;24(5):1844–1854
  19. Ahmad F, Goldstein BJ. Functional association between the insulin receptor and the transmembrane protein-tyrosine phosphatase LAR in intact cells. The Journal of Biological Chemistry. 1997 Jan 3;272(1):448–457
  20. Zhang WR, Li PM, Oswald MA, et al. Modulation of insulin signal transduction by eutopic overexpression of the receptor-type protein-tyrosine phosphatase LAR. Molecular Endocrinology. 1996 May;10(5):575–584
  21. Li PM, Zhang WR, Goldstein BJ. Suppression of insulin receptor activation by overexpression of the protein-tyrosine phosphatase LAR in hepatoma cells. Cell Signal. 1996 Nov;8(7):467–473
  22. Kulas DT, Goldstein BJ, Mooney RA. The transmembrane protein-tyrosine phosphatase LAR modulates signaling by multiple receptor tyrosine kinases. The Journal of Biological Chemistry. 1996 Jan 12;271(2):748–754
  23. Kulas DT, Zhang WR, Goldstein BJ, et al. Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR. The Journal of Biological Chemistry. 1995 Feb 10;270(6):2435–2438
  24. Ren JM, Li PM, Zhang WR, et al. Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. Diabetes. 1998 Mar;47(3):493–497
  25. Zabolotny JM, Kim YB, Peroni OD, et al. Overexpression of the LAR (leukocyte antigen-related) protein-tyrosine phosphatase in muscle causes insulin resistance. Proceedings of the National Academy of Sciences of the United States of America. 2001 Apr 24;98(9):5187–5192
  26. Chagnon MJ, Uetani N, Tremblay ML. Functional significance of the LAR receptor protein tyrosine phosphatase family in development and diseases. Biochemistry and Cell Biology. 2004 Dec;82(6):664–675
  27. Moller NP, Moller KB, Lammers R, et al. Selective down-regulation of the insulin receptor signal by protein-tyrosine phosphatases alpha and epsilon. The Journal of Biological Chemistry. 1995 Sep 29;270(39):23126–23131
  28. Lammers R, Moller NP, Ullrich A. The transmembrane protein tyrosine phosphatase alpha dephosphorylates the insulin receptor in intact cells. FEBS Letters. 1997 Mar 3;404(1):37–40
  29. Cong LN, Chen H, Li Y, et al. Overexpression of protein tyrosine phosphatase-alpha (PTP-alpha) but not PTP-kappa inhibits translocation of GLUT4 in rat adipose cells. Biochemical and Biophysical Research communications. 1999 Feb 16;255(2):200–207
  30. Arnott CH, Sale EM, Miller J, et al. Use of an antisense strategy to dissect the signaling role of protein-tyrosine phosphatase alpha. The Journal of Biological Chemistry. 1999 Sep 10;274(37):26105–26112
  31. Su J, Muranjan M, Sap J. Receptor protein tyrosine phosphatase alpha activates Src-family kinases and controls integrin-mediated responses in fibroblasts. Current Biology. 1999 May 20;9(10):505–511
  32. Le HT, Ponniah S, Pallen CJ. Insulin signaling and glucose homeostasis in mice lacking protein tyrosine phosphatase alpha. Biochemical and Biophysical Research communications. 2004 Feb 6;314(2):321–329
  33. Rocchi S, Tartare-Deckert S, Sawka-Verhelle D, et al. Interaction of SH2-containing protein tyrosine phosphatase 2 with the insulin receptor and the insulin-like growth factor-I receptor: studies of the domains involved using the yeast two-hybrid system. Endocrinology. 1996 Nov;137(11):4944–4952
  34. Tenev T, Keilhack H, Tomic S, et al. Both SH2 domains are involved in interaction of SHP-1 with the epidermal growth factor receptor but cannot confer receptor-directed activity to SHP-1/SHP-2 chimera. The Journal of Biological Chemistry. 1997 Feb 28;272(9):5966–5973
  35. Hayashi K, Shibata K, Morita T, et al. Insulin receptor substrate-1/SHP-2 interaction, a phenotype-dependent switching machinery of insulin-like growth factor-I signaling in vascular smooth muscle cells. The Journal of Biological Chemistry. 2004 Sep 24;279(39):40807–40818
  36. Milarski KL, Saltiel AR. Expression of catalytically inactive Syp phosphatase in 3T3 cells blocks stimulation of mitogen-activated protein kinase by insulin. The Journal of Biological Chemistry. 1994 Aug 19;269(33):21239–21243
  37. Fukunaga K, Noguchi T, Takeda H, et al. Requirement for protein-tyrosine phosphatase SHP-2 in insulin-induced activation of c-Jun NH(2)-terminal kinase. The Journal of Biological Chemistry. 2000 Feb 18;275(7):5208–5213
  38. Chen H, Wertheimer SJ, Lin CH, et al. Protein-tyrosine phosphatases PTP1B and syp are modulators of insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. The Journal of Biological Chemistry. 1997 Mar 21;272(12):8026–8031
  39. Clemmons DR, Maile LA. Minireview: integral membrane proteins that function coordinately with the Insulin-like Growth Factor 1 Receptor to regulate intracellular signaling. Endocrinology. 2003;144(5):1664–1670
  40. Arrandale JM, Gore-Willse A, Rocks S, et al. Insulin signaling in mice expressing reduced levels of Syp. The Journal of Biological Chemistry. 1996 Aug 30;271(35):21353–21358
  41. Maegawa H, Hasegawa M, Sugai S, et al. Expression of a dominant negative SHP-2 in transgenic mice induces insulin resistance. The Journal of Biological Chemistry. 1999 Oct 15;274(42):30236–30243
  42. Tartaglia M, Gelb BD. Noonan syndrome and related disorders: genetics and pathogenesis. Annual Review of Genomics and Human Genetics. 2005;6:45–68
  43. Araki T, Mohi MG, Ismat FA, et al. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Natural Medicines. 2004 Aug;10(8):849–857
  44. Mohi MG, Neel BG. The role of Shp2 (PTPN11) in cancer. Current Opinion in Genetics & Development. 2007 Feb;17(1):23–30
  45. Tillmann U, Wagner J, Boerboom D, et al. Nuclear localization and cell cycle regulation of a murine protein tyrosine phosphatase. Molecular and Cellular Biology. 1994 May;14(5):3030–3040
  46. You-Ten KE, Muise ES, Itie A, et al. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. The Journal of Experimental Medicine. 1997 Aug 29;186(5):683–693
  47. Walchli S, Curchod ML, Gobert RP, et al. Identification of tyrosine phosphatases that dephosphorylate the insulin receptor. A brute force approach based on ‘substrate-trapping’ mutants. The Journal of Biological Chemistry. 2000 Mar 31;275(13):9792–9796
  48. Galic S, Klingler-Hoffmann M, Fodero-Tavoletti MT, et al. Regulation of insulin receptor signaling by the protein tyrosine phosphatase TCPTP. Molecular and Cellular Biology. 2003 Mar;23(6):2096–2108
  49. Galic S, Hauser C, Kahn BB, et al. Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Molecular and Cellular Biology. 2005 Jan;25(2):819–829
  50. Tonks NK, Diltz CD, Fischer EH. Purification of the major protein-tyrosine-phosphatases of human placenta. The Journal of Biological Chemistry. 1988 May 15;263(14):6722–6730
  51. Frangioni JV, Beahm PH, Shifrin V, et al. The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence. Cell. 1992 Feb 7;68(3):545–560
  52. Brown-Shimer S, Johnson KA, Lawrence JB, et al. Molecular cloning and chromosome mapping of the human gene encoding protein phosphotyrosyl phosphatase 1B. Proceedings of the National Academy of Sciences of the United States of America. 1990 Jul;87(13):5148–5152
  53. Florez JC, Hirschhorn J, Altshuler D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annual Review of Genomics and Human Genetics. 2003;4:257–291
  54. Echwald SM, Bach H, Vestergaard H, et al. A P387L variant in protein tyrosine phosphatase-1B (PTP-1B) is associated with type 2 diabetes and impaired serine phosphorylation of PTP-1B in vitro. Diabetes. 2002 Jan;51(1):1–6
  55. Mok A, Cao H, Zinman B, et al. A single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose tolerance in Oji-Cree. The Journal of Clinical Endocrinology and Metabolism. 2002 Feb;87(2):724–727
  56. Di Paola R, Frittitta L, Miscio G, et al. A variation in 3' UTR of hPTP1B increases specific gene expression and associates with insulin resistance. American Journal of Human Genetics. 2002 Mar;70(3):806–812
  57. Bento JL, Palmer ND, Mychaleckyj JC, et al. Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2 diabetes. Diabetes. 2004 Nov;53(11):3007–3012
  58. Florez JC, Agapakis CM, Burtt NP, et al. Association testing of the protein tyrosine phosphatase 1B gene (PTPN1) with type 2 diabetes in 7,883 people. Diabetes. 2005 Jun;54(6):1884–1891
  59. Traurig M, Hanson RL, Kobes S, et al. Protein tyrosine phosphatase 1B is not a major susceptibility gene for type 2 diabetes mellitus or obesity among Pima Indians. Diabetologia. 2007 May;50(5):985–989
  60. Cheyssac C, Lecoeur C, Dechaume A, et al. Analysis of common PTPN1 gene variants in type 2 diabetes, obesity and associated phenotypes in the French population. BMC Medical Genetics. 2006;7:44
  61. Seely BL, Staubs PA, Reichart DR, et al. Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes. 1996 Oct;45(10):1379–1385
  62. Bandyopadhyay D, Kusari A, Kenner KA, et al. Protein-tyrosine phosphatase 1B complexes with the insulin receptor in vivo and is tyrosine-phosphorylated in the presence of insulin. The Journal of Biological Chemistry. 1997 Jan 17;272(3):1639–1645
  63. Cicirelli MF, Tonks NK, Diltz CD, et al. Microinjection of a protein-tyrosine-phosphatase inhibits insulin action in Xenopus oocytes. Proceedings of the National Academy of Sciences of the United States of America. 1990 Jul;87(14):5514–5518
  64. Goldstein BJ, Bittner-Kowalczyk A, White MF, et al. Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. The Journal of Biological Chemistry. 2000 Feb 11;275(6):4283–4289
  65. Ahmad F, Li PM, Meyerovitch J, et al. Osmotic loading of neutralizing antibodies demonstrates a role for protein-tyrosine phosphatase 1B in negative regulation of the insulin action pathway. The Journal of Biological Chemistry. 1995 Sep 1;270(35):20503–20508
  66. Venable CL, Frevert EU, Kim YB, et al. Overexpression of protein-tyrosine phosphatase-1B in adipocytes inhibits insulin-stimulated phosphoinositide 3-kinase activity without altering glucose transport or Akt/Protein kinase B activation. The Journal of Biological Chemistry. 2000 Jun 16;275(24):18318–18326
  67. Egawa K, Maegawa H, Shimizu S, et al. Protein-tyrosine phosphatase-1B negatively regulates insulin signaling in l6 myocytes and Fao hepatoma cells. The Journal of Biological Chemistry. 2001 Mar 30;276(13):10207–10211
  68. Asante-Appiah E, Kennedy BP. Protein tyrosine phosphatases: the quest for negative regulators of insulin action. American Journal of Physiology. Endocrinology and Metabolism. 2003 Apr;284(4):E663–E670
  69. Elchebly M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 1999 Mar 5;283(5407):1544–1548
  70. Klaman LD, Boss O, Peroni OD, et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Molecular and Cellular Biology. 2000 Aug;20(15):5479–5489
  71. Haj FG, Markova B, Klaman LD, et al. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B. The Journal of Biological Chemistry. 2003 Jan 10;278(2):739–744
  72. Haj FG, Zabolotny JM, Kim YB, et al. Liver-specific protein-tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B-/-mice. The Journal of Biological Chemistry. 2005 Apr 15;280(15):15038–15046
  73. Zinker BA, Rondinone CM, Trevillyan JM, et al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proceedings of the National Academy of Sciences of the United States of America. 2002 Aug 20;99(17):11357–11362
  74. Korner J, Aronne LJ. The emerging science of body weight regulation and its impact on obesity treatment. The Journal of Clinical Investigation. 2003 Mar;111(5):565–570
  75. Kaszubska W, Falls HD, Schaefer VG, et al. Protein tyrosine phosphatase 1B negatively regulates leptin signaling in a hypothalamic cell line. Molecular and Cellular Endocrinology. 2002 Sep 30;195(1–2):109–118
  76. Lund IK, Hansen JA, Andersen HS, et al. Mechanism of protein tyrosine phosphatase 1B-mediated inhibition of leptin signalling. Journal of Molecular Endocrinology. 2005 Apr;34(2):339–351
  77. Rondinone CM, Trevillyan JM, Clampit J, et al. Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis. Diabetes. 2002 Aug;51(8):2405–2411
  78. Cheng A, Uetani N, Simoncic PD, et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Developmental Cell. 2002 Apr;2(4):497–503
  79. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, et al. PTP1B regulates leptin signal transduction in vivo. Developmental Cell. 2002 Apr;2(4):489–495
  80. Lam NT, Covey SD, Lewis JT, et al. Leptin resistance following over-expression of protein tyrosine phosphatase 1B in liver. Journal of Molecular Endocrinology. 2006 Feb;36(1):163–174
  81. Morrison CD, White CL, Wang Z, et al. Increased hypothalamic protein tyrosine phosphatase 1B contributes to leptin resistance with age. Endocrinology. 2007 Jan;148(1):433–440
  82. Jia Z, Barford D, Flint AJ, et al. Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B. Science. 1995 Jun 23;268(5218):1754–1758
  83. Puius YA, Zhao Y, Sullivan M, et al. Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design. Proceedings of the National Academy of Sciences of the United States of America. 1997 Dec 9;94(25):13420–13425
  84. Salmeen A, Andersen JN, Myers MP, et al. Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. Molecular Cell. 2000 Dec;6(6):1401–1412
  85. Iversen LF, Moller KB, Pedersen AK, et al. Structure determination of T cell protein-tyrosine phosphatase. The Journal of Biological Chemistry. 2002 May 31;277(22):19982–19990
  86. Shen K, Keng YF, Wu L, et al. Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. The Journal of Biological Chemistry. 2001 Dec 14;276(50):47311–47319
  87. Xin Z, Oost TK, Abad-Zapatero C, et al. Potent, selective inhibitors of protein tyrosine phosphatase 1B. Bioorganic & Medicinal Chemistry Letters. 2003 Jun 2;13(11):1887–1890
  88. Asante-Appiah E, Patel S, Desponts C, et al. Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase. The Journal of Biological Chemistry. 2006 Mar 24;281(12):8010–8015
  89. Fantus IG, Kadota S, Deragon G, et al. Pervanadate [Peroxide(s) of Vanadate] mimics insulin action in rat adipocytes via activation of the insulin receptor tyrosine kinase. Biochemistry. 1989;28:8864–8871
  90. Posner BI, Faure R, Burgess JW, et al. Peroxovanadium compounds: a new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. The Journal of Biological Chemistry. 1994;269:4596–4604
  91. Cohen N, Halberstam M, Shlimovich P, et al. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. The Journal of Clinical Investigation. 1995 Jun;95(6):2501–2509
  92. Groves MR, Yao ZJ, Roller PP, et al. Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics. Biochemistry. 1998 Dec 22;37(51):17773–17783
  93. Taylor SD, Hill B. Recent advances in protein tyrosine phosphatase 1B inhibitors. Expert Opinion on Investigational Drugs. 2004 Mar;13(3):199–214
  94. Sarmiento M, Puius YA, Vetter SW, et al. Structural basis of plasticity in protein tyrosine phosphatase 1B substrate recognition. Biochemistry. 2000 Jul 18;39(28):8171–8179
  95. Yao ZJ, Ye B, Wu XW, et al. Structure-based design and synthesis of small molecule protein-tyrosine phosphatase 1B inhibitors. Bioorganic & Medicinal Chemistry. 1998 Oct;6(10):1799–1810
  96. Wrobel J, Sredy J, Moxham C, et al. PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes. Journal of Medicinal Chemistry. 1999 Aug 26;42(17):3199–3202
  97. Tobin JF, Tam S. Recent advances in the development of small molecule inhibitors of PTP1B for the treatment of insulin resistance and type 2 diabetes. Current Opinion in Drug Discovery & Development. 2002 Jul;5(4):500–512
  98. Peterson RL, Casciotti L, Block L, et al. Mechanistic toxicogenomic analysis of WAY-144122 administration in Sprague-Dawley rats. Toxicology and Applied Pharmacology. 2004 Apr 1;196(1):80–94
  99. Erbe DV, Wang S, Zhang YL, et al. Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. Molecular Pharmacology. 2005 Jan;67(1):69–77
  100. Julien SG, Dube N, Read M, et al. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nature Genetics. 2007 Mar;39(3):338–346
  101. Bentires-Alj M, Neel BG. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Research. 2007 Mar 15;67(6):2420–2424
  102. Kamerlin SCL, Rucker R, Boresch S. A molecular dynamics study of WPD-loop flexibility in PTP1B. Biochemical and Biophysical Research communications. 2007 Mar 13;356:1011–1016
  103. Zhang S, Zhang Z-Y. PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discovery Today. 2007, May 12;9/10:373–381
  104. Andersen JN, Elson A, Lammers R, et al. Comparative study of protein tyrosine phosphatase-epsilon isoforms: membrane localization confers specificity in cellular signaling. Biochemical Journal. 2001 Mar 15;354(Pt 3):581–590
  105. Pandey SK, Yu XX, Watts LM, et al. Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice. The Journal of Biological Chemistry. 2007 May 11;282(19):14291–14299
  106. Cho CY, Koo SH, Wang Y, et al. Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling. Cell Metabolism. 2006 May 3;(5):367–378
  107. Myers MG. Leptin receptor signaling and the regulation of mammalian physiology. Recent Progress in Hormonal Research. 2004;59:287–304

PII: S1521-690X(07)00081-4

doi: 10.1016/j.beem.2007.08.004

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 4 , Pages 621-640 , December 2007

Article Tools

* Image Usage & Resolution